EVE-106 Novel Estrogen

Alternative Name: EVE-106; EVE106; ethinylestradiol prodrugs

Description: EVE-106 is a new chemical entity with validated animal data. A combination of drospirenone (DRSP) and EC-300 (Evestra's test compound), this estrogen receptor agonist is being developed with hopes of utilizing the benefits of DRSP while avoiding the safety issues of ethinyl estradiol (EE).

Product Details

User: Female

Hormonal: Yes

Multipurpose Preventive Technology (MPT): No

Status Details

Developer: Evestra, Inc.

Project Phase: Pre-Clinical and Clinical Development

Development Stage: Pre-clinical

Began discovery in: Prior to 2008

Active Development: Unknown

Additional Information

References:

Vertical Tabs

Print